Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2014;41(4):2629-34.
doi: 10.1007/s11033-014-3121-x. Epub 2014 Feb 18.

The association between the Lys751Gln polymorphism in the XPD gene and the risk of bladder cancer

Tianyuan Xiong  1 , Jiqiao Yang, Haichuan Wang, Fanyi Wu, Yang Liu, Rui Xu, Zi Lv, Pei Xue, Wen Cao, Yonggang Zhang
Affiliations
Meta-Analysis

The association between the Lys751Gln polymorphism in the XPD gene and the risk of bladder cancer

Tianyuan Xiong et al. Mol Biol Rep. 2014.

Abstract

The Lys751Gln polymorphism in the XPD gene have been suggested as a risk factor for bladder cancer, however the results were inconclusive. The aim of the current study is to assess the association by meta-analysis. A total of 15 case-control studies concerning the association between the XPD Lys751Gln polymorphism and bladder cancer risk were included in the meta-analysis. The results suggested that the Lys751Gln polymorphism was not associated with an increased risk of bladder cancer in the dominant model (OR = 1.03, 95 % CI 0.95-1.11, P = 0.53 for Lys/Gln+Gln/Gln vs. Lys/Lys) in overall analysis. In the subgroup analysis by ethnicity, no significant association was found in Caucasians or Asians. Other comparatives suggested a slight significant association between the polymorphism with the risk of bladder cancer in the recessive comparative (OR = 1.14, 95 % CI 1.02-1.29, P = 0.03). The current meta-analysis indicated that the Lys751Gln polymorphism in the XPD gene might be a risk factor for bladder cancer. In the future, more large-scale case-control studies are needed to validate our results.

PubMed Disclaimer

References

    1. Mol Biol Rep. 2013 May;40(5):3483-91 - PubMed
    1. Mol Biol Rep. 2013 Mar;40(3):2581-7 - PubMed
    1. Cancer Genet Cytogenet. 2007 Aug;177(1):30-6 - PubMed
    1. Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1234-40 - PubMed
    1. Hum Hered. 2008;65(2):105-18 - PubMed

Publication types

LinkOut - more resources